Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

72.4K
Overview
72.4K
Tissue Transplantation01:24

Tissue Transplantation

519
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
519
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

4.5K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
4.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

ALLOPLUS: allogeneic hematopoietic stem cell transplantation in children and adult people living with human immunodeficiency virus, a retrospective study of the SFGM-TC.

Bone marrow transplantation·2026
Same author

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026
Same author

Claudio Bordignon.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Proof-of-principle 4-marker spatial profiling reveals distinct, location-independent immune clusters in biliary tract cancers.

Pathology oncology research : POR·2026
Same author

Long-term remission of neuromyelitis optica with allogeneic hematopoietic stem cell transplant.

Med (New York, N.Y.)·2026
Same author

Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case Report.

Case reports in hematology·2026

相关实验视频

Updated: Sep 10, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

超越传统的采用T细胞疗法

Marina Cavazzana1, Juliette Paillet2, Abderrahim Fandi2

  • 1Department of Biotherapy Clinical Investigation Center, AP-HP, Hôpital Necker-Enfants Malades, Paris, France; Smart Immune, Paris, France.

The Journal of allergy and clinical immunology
|August 23, 2025
PubMed
概括

通过一种新的无料系统生成人类T淋巴细胞原始体 (HTLP) 是治疗T细胞缺陷的一个有希望的方法. 这种免疫疗法可以增强干细胞移植后的免疫复合.

关键词:
其他类型血造干细胞移植免疫复制剂淋巴发育一个T细胞的祖先T 淋巴细胞甲状腺

更多相关视频

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.8K

相关实验视频

Last Updated: Sep 10, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.8K

科学领域:

  • 免疫学
  • 细胞生物学
  • 生物技术

背景情况:

  • 缺少T细胞会影响免疫功能,增加感染和复发的风险,特别是在对血液恶性瘤进行全源造血干细胞移植后.
  • 目前采用T细胞疗法在特异性,安全性,可扩展性和制造方面面临挑战,需要替代免疫复合策略.

研究的目的:

  • 评估基于人类T淋巴细胞原体 (HTLP) 的免疫疗法作为对T细胞缺陷当前治疗的补充方法的潜力.
  • 总结关于产生HTLP的新型无料培养系统的临床前和临床研究,并评估其免疫复合的优势和局限性.

主要方法:

  • 使用人类DLL4-Fc融合蛋白 (Notch配体) 来在7天内从CD34+造血干细胞和祖细胞产生HTLP的无养殖系统的开发.
  • 由此产生的细胞产品,ProTcell的特征,识别了关键的表面标记物,如CD7,CCR9和L-选择素.
  • 在注射到NSG小鼠后,评估ProTcell对T细胞的分化和胸膜形成的能力.

主要成果:

  • 一个无料培养系统成功地在7天内从造血干细胞和原始细胞产生HTLP (ProTcell).
  • ProTcell包括表达CD7,CCR9和L-选择素的细胞,表明淋巴原体的身份.
  • 在体内研究表明,注射的ProTcell可以在NSG小鼠的胸腺内分化并成熟为T细胞.

结论:

  • 基于HTLP的免疫疗法,通过描述的无料系统产生,为T细胞缺乏症的免疫复合提供了可行的和潜在的优势策略.
  • 这种方法可以克服当前T细胞治疗的局限性,并改善接受干细胞移植或患有免疫疾病的患者的治疗结果.
  • 需要进一步的临床前和临床研究,以充分确定ProTcell的安全性,疗效和可扩展性.